secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001193125-23-169021
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics stockholders approve equity plan expansion and re-elect directors at 2023 annual meeting
--------------------------------------------------------------------------------

- Stockholders approved Amended and Restated 2023 Equity Incentive Plan, increasing authorized shares by 1,150,000.
- Re-elected Thomas Dubensky and Christine Pellizzari as Class II directors to serve until 2026.
- Advisory vote on executive compensation approved with 7,355,907 votes for, 55,375 against.
- Ratified Ernst & Young as independent registered public accounting firm for fiscal 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/0001193125-23-169021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312523169021/d512429d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-169021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer